Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $925
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has maintained a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $850 to $925.

February 06, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained a Neutral rating on Regeneron Pharmaceuticals but raised the price target from $850 to $925.
The increase in price target by Cantor Fitzgerald suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a positive impact on the stock price. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, which might temper expectations for a significant price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100